SCHEMBL5036142

SCHEMBL5036142

COc1ccc(-c2ccc(F)cc2)c2oc(NC(=O)Cc3ccccc3)nc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.46
MEN1 O00255 4/20 0.46
PI4KB Q9UBF8 1/20 0.45
IMPDH2 P12268 1/20 0.44
AAK1 Q2M2I8 1/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
POLB P06746 2/20 0.43
MAPT P10636 2/20 0.43
RXFP1 Q9HBX9 2/20 0.43
HPGD P15428 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5131523 0.87 HTT (0.43) KMT2AKDM4EALDH1A1POLBHPGD
SCHEMBL5037775 0.86 ALDH1A1 (0.45) KMT2AMEN1ALDH1A1POLBMAPT
SCHEMBL5036203 0.83 ALDH1A1 (0.41) KMT2AMEN1KDM4EALDH1A1POLB
SCHEMBL5036500 0.83 HTT (0.54) KMT2AKDM4EALDH1A1POLBMAPT
SCHEMBL5037699 0.81 ADCY1 (0.51) KMT2AMEN1KDM4EPOLBMAPT
SCHEMBL5036662 0.75 ADORA2A (0.56) KMT2AMEN1IMPDH2AAK1KDM4E
SCHEMBL5033495 0.75 ADCY1 (0.42) KMT2AMEN1AAK1KDM4EALDH1A1
SCHEMBL5033611 0.74 ADORA2A (0.47) KMT2AKDM4EALDH1A1POLBMAPT
SCHEMBL5037899 0.74 ADCY1 (0.44) KMT2AMEN1AAK1KDM4EPOLB
SCHEMBL5040819 0.74 ADORA2A (0.47) KMT2AAAK1KDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1587799-B1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2008-03-12 EP disclosed
US-6992083-B2 deiodination/arylation, acylation or hydrogenation of a substituted 4-methoxy-bezoxazole derivative; adenosine receptor ligands; Parkinson's and Alzheimer's Diseases; 2-Chloromethyl-N-[7-(4-fluoro-phenyl)-4-methoxy-benzooxazol-2-yl]-isonicotinamide HOFFMAN-LA ROCHE INC. (US) 2006-01-31 US disclosed
EP-1587799-A1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-26 EP disclosed
US-20040152702-A1 Benzoxazol derivatives F. HOFFMANN-LA ROCHE AG (CH) 2004-08-05 US disclosed
WO-2004063177-A1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152702-A1 Benzoxazol derivatives P2RX3, P2RX2, P2RX1 KMT2A 1662/4885MEN1 3710/4885PI4KB 1417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.